Rheumatologic symptoms in oncologic patients on PD-1 inhibitors

Immune check-point inhibitors are effective cancer therapies that have been associated with immune related adverse events (irAEs). Recent reports of irAEs describe symptoms resembling classic rheumatologic syndromes, most notably associated with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor blockade. There are limited reports of rheumatologic disease associated with programmed cell death protein-1 (PD-1) inhibitors. Here, we describe a case series of four patients presenting to the Brigham and Women's Hospital (BWH) Arthritis Center with de novo polymyalgia rheumatica (PMR)-type conditions and/or peripheral synovitis after treatment with PD-1/PD-Ligand 1 (PD-L1) pathway inhibitors.

Source: Seminars in Arthritis and Rheumatism - October 30, 2017 Category: Rheumatology Authors: Wilson F. Kuswanto, Lindsey A. MacFarlane, Lydia Gedmintas, Alexandra Mulloy, Toni K. Choueiri, Bonnie Bermas Source Type: research